Eli Lilly reported phase 2 data showing its amylin receptor agonist eloralintide produced dose‑dependent weight loss—up to 20.1% at Week 48—and said it will move the program into Phase 3. The trial enrolled adults with obesity or overweight plus at least one comorbidity; higher‑dose cohorts achieved the largest mean reductions while tolerability improved with slower titration. Lilly positioned eloralintide as a differentiated amylin candidate with increased selectivity for amylin receptors versus calcitonin receptors, a design intended to optimize efficacy and limit off‑target effects. The company cited lower rates of gastrointestinal adverse events with slower escalation and will initiate registrational work next month. The data sharpen competition in the nascent amylin class and add pressure to incumbents advancing GLP‑1 and combination strategies. Investors and competitors will watch Phase 3 design choices and safety monitoring as the company seeks to convert strong weight‑loss signals into a regulatory claim.